An in-depth look at the leading psychedelic stocks in the U.S. stock market this year. Here's what you need to know.

Cathie Wood's ARK added to its Meta Platforms (NASDAQ:META) position while further reducing its stake in Advanced Micro Devices (NASDAQ:AMD), according to the firm's daily trade disclosure released ...

At its core, Tabu is redefining how the world perceives her unconventional life and career by shifting the narrative from ...

Cathie Wood, head of Ark Investment Management, is known for buying her favorite tech stocks during market pullbacks. That's exactly what she just did, adding shares of an AI stock after a sharp ...

COMPASS Pathways stock has delivered a very strong 1 year return, yet its current valuation checks and market multiples point ...

Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, ...

Compass Pathways (CMPS) stock gains as Evercore ISI upgraded the company on the latest Phase 3 trial data for the company's ...

Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.

New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...

Compass Pathways plc CMPS on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the ...

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.

Compass Pathways posted 26-week data from its trial evaluating COMP360, showing rapid and durable benefits, while maintaining ...